Want to see NSPR full AI Analyst Report?
NSPR Stock Chart & Stats
$0.68
-$0.01(-1.63%)
At close: 4:00 PM EDT
$0.68
-$0.01(-1.63%)
Day’s Range― - ―
52-Week Range$0.63 - $2.93
Previous CloseN/A
Volume15.57K
Average Volume (3M)102.59K
Market Cap
$30.45M
Enterprise Value$98.14
Total Cash (Recent Filing)$41.57M
Total Debt (Recent Filing)$3.11M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Aug 11, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding46,838,963
10 Day Avg. Volume68,719
30 Day Avg. Volume102,589
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.37
Price to Sales (P/S)14.56
P/FCF Ratio-3.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.67Price Target Upside439.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.74
Revenue Forecast (FY)$10.38M
Bulls Say, Bears Say
Bulls Say
Large Clinical Installed BaseA 70,000+ global installed base and strong physician demand represent durable adoption and real-world validation. That scale supports continued clinical preference, referral networks, and repeat purchasing, lowering commercial friction as the company expands indications and geographies over months.
Regulatory & Clinical ProgressConcrete regulatory milestones and trial starts create structural optionality: approvals and TCAR indications would materially expand the U.S. addressable market and enable new procedural adoption, providing a multi‑quarter runway for revenue scale if outcomes and clearances proceed as planned.
Low Financial LeverageVery low debt lowers bankruptcy and interest burden risk, giving the company flexibility to fund remediation, trials, or targeted commercial investments without immediate interest pressure. That structural balance-sheet strength eases near-term liquidity stress despite operating losses.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow indicates the business currently consumes material capital to fund operations. Over a multi‑month horizon this necessitates external financing or material margin/revenue improvement, raising dilution and execution risk if approvals or launches are delayed.
Deep UnprofitabilityProfitability metrics show the cost base is far ahead of current sales scale: persistent multi‑hundred percent negative margins imply the company must materially grow revenue or cut costs to reach sustainability, a structural challenge that could take multiple quarters to resolve.
U.S. Commercial Pause / RecallA voluntary U.S. pause directly halts rollout in the largest per‑procedure market and forced withdrawal of guidance. Even if technical (not implant) issues, regulatory remediation and relaunch timelines create sustained headwinds to U.S. revenue growth and delay scale-up of the TCAR strategy.
InspireMD News
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $0.63 and its highest was $2.93 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $30.45M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Aug 11, 2026 which is in 9 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on May 04, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.02.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.2.
How many shares outstanding does InspireMD have?
InspireMD has 46,838,963 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went down -5.983%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.67 (439.22% Upside)
$3.67 (439.22% Upside)
Insider Transactions
Bought Shares
Worth $176.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.03%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary interventions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
NSPR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong commercial traction and substantial year-over-year revenue growth (122%), expanding international sales (48% YoY), a large clinical installed base (>70,000 cases), and clear regulatory/clinical pathways (C-GUARDIANS III initiation, expected approvals). Offsetting these positives is a material near-term operational setback — a voluntary U.S. pause/recall of the CGuard Prime 135 delivery system — which led to impairment charges, planned reserves (~$1.35M combined), withdrawal of 2026 revenue guidance, increased operating expenses, and reduced cash versus year-end. Management characterizes the issue as technical (not implant safety), has identified root causes, and expects a path to remediation and relaunch, but timing is uncertain. Overall, the call balances strong growth and long-term opportunity with a meaningful short-term commercial disruption and financial impact.View all NSPR earnings summariesNSPR Stock 12 Month Forecast
Average Price Target
$3.67
▲(439.22% Upside)
Technical Analysis
Ownership Overview
21.29% Insiders
0.04% Mutual Funds
0.77% Other Institutional Investors
77.65% Public Companies and
Individual Investors